We are working for the cure!
Because leiomyosarcoma is so rare, it is critical to get a second opinion or treatment at a high volume sarcoma center. Patients who get treated at sarcoma centers have been shown to have better outcomes and longer survival.
Learn more about Leiomyosarcoma (LMS) symptoms, causes, and treatment.
Since 2006, LMSDR’s mission is to empower patients with information and support, fund groundbreaking LMS research, and provide a bridge between patients and researchers to collaborate on finding a cure.
Newly diagnosed with LMS? Call us for help navigating this new journey.
Caregivers are encouraged to call us too! 1-866-912-2730
New therapies for LMS tumors can’t be discovered until we systematically map the best drug targets. The Rare Cancer Dependency Map Initiative is creating patient models from living tissue and using CRISPR/drug data to help researchers worldwide solve this challenge, together.
Working – not hoping – for a cure.
Choose to Trust: Faith and Pragmatism tackling Cancer
New book by LMS patient Bruce Stevens – 100% proceeds go to LMSDR
Whether as a patient or a family member, the chances are everyone will be faced with cancer at some stage in their life. Bruce shares his journey of tackling cancer warts and all, from the challenge of telling people through to coming to grips with losing control. He also explores how his Christian faith intersects with this health crisis. If you find yourself in this situation, this will really help you grapple with practical issues. BUY ON AMAZON
LMSDR JOINS NCI’s MyPart Program
In the MyPART network, NCI’s mission is to engage patients as partners in rare tumor research. LMSDR is a critical bridge between patients and researchers, helping share experiences and expertise between these important stakeholders. LMSDR will participate in Rare Tumor Workshops and provide input on research issues important to LMS. We will also share MyPart clinical trials, research opportunities and news, so that you can get involved. Participate! If you are a young adult or have a child with LMS, you can contribute to the Natural History Study of Rare Solid Tumors. You can help the researchers learn about LMS and how to best help us.
LMS Blood Drive Update
Grant Awards for LMS Research 2020
$150,000 second year funding SARC for their continued work on looking at new targets for LMS, including the role of TP53, pten, p13K and mTOR.
$100,000 to Matt van de Rijn to create a blood test to distinguish leiomyosarcoma from benign uterine fibroids. This is a two-year project.
Read about past years awards:
Updates on lmsdr
New Board Member at Certis Oncology
Fritz Eilber, MD, UCLA Surgery Division of Oncology discusses why he joined the Board of Directors at Certis Oncology. Certis provides Orthotopic PDX (Patient-Derived Xenograft) mouse models for cancer patients.